H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Pluristem (PSTI) today and set a price target of $3.50. The company’s shares closed yesterday at $1.01.
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -2.9% and a 36.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Collplant Holdings Ltd.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pluristem with a $3.25 average price target.
See today’s analyst top recommended stocks >>
Based on Pluristem’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $8.68 million. In comparison, last year the company had a GAAP net loss of $8.23 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pluristem Therapeutics, Inc. is a biotechnology company, which engages in the provision of cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions.
